Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

• First patient with MC1R-positive metastatic melanoma treated with ²¹²Pb-VMT01
  
• Preliminary data readout from dose escalation study expected Q4 2023
  
  

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) --   Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at the University of Wisconsin in the Company’s Phase 1/2a dose escalation trial evaluating the safety and efficacy of ²¹²Pb-VMT01 in patients with MC1R+ metastatic melanoma. The trial is a first-in-human, non-randomized, multi-center open-label dose escalation, dose expansion study of ²¹²Pb-VMT01 in patients with histologically confirmed melanoma and a positive MC1R imaging scan.

“MC1R is implicated in the development of melanoma making it a promising target for potential treatment using radionuclide therapy,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. “Today we achieved an important milestone as we work to access the potential of VMT01 as a targeted alpha-particle therapy for MC1R+ metastatic melanoma."

“We are excited to work with Perspective and announce that the first patient with metastatic melanoma has been dosed in the first-in-human study of ²¹²Pb-VMT01," said Zachary S. Morris, M.D., Ph.D., Vice Chair and Endowed Professor of Human Oncology, Program Director for the University of Wisconsin Bentson Research Fellowship, and Principal Investigator for the VMT01 clinical study. "With Perspective’s targeted radionuclide therapy, ²¹²Pb-VMT01, we have the advantage of treating all disease sites following intravenous injection.”

VMT01 has recently completed clinical imaging studies at Mayo Clinic, Rochester. Results were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Chicago. In addition, published preclinical data demonstrated durable complete responses in treatment-resistant models when combined with existing immunotherapy drugs used to treat melanoma.

“With the successful conclusion of our imaging study, we are excited to proceed with Perspective’s first-in-human dosing of ²¹²Pb-VMT01,” said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics. “As we advance through development milestones, our goal is to demonstrate ²¹²Pb-VMT01 can deliver systemic, precision, cytotoxic alpha particle radiation in order to selectively kill cancer cells. We look forward to presenting preliminary data from the study later in the year.”